Search PubMed⌕ Search

Biomedical subjects

W B Shingleton

Publications and source records attributed to W B Shingleton.

16 recordsLinked to original sources
PubMed1999

A randomized prospective study of laser ablation of the prostate versus transurethral resection of the prostate in men with benign prostatic hyperplasia.

OBJECTIVES: To compare the safety and efficacy of laser ablation of the prostate, one of the minimally invasive treatments available for men with benign prostatic hyperplasia, to transurethral resection of the prostate (TURP). METHODS: A prospective randomized study of 100 men with benign prostatic hyperplasia, with 50 patients in each treatment arm, was conducted. All patients met the entry criteria: age older than 45 years, no history of carcinoma of the prostate, a peak flow rate less than 15 mL/s, medical therapy failure, and the ability to undergo regional or general anesthesia. All patients underwent a preoperative evaluation consisting of the American Urological Association (AUA) symptom score, uroflowmetry, pressure-flow study, transrectal ultrasound for prostate volume, and serum prostate-specific antigen determination. Patients underwent either TURP or laser ablation of the prostate using the potassium titanyl phosphate (KTP)/neodymium: yttrium-aluminum-garnet laser. Patients were seen for follow-up at 1, 3, 6, and 12 months. RESULTS: The mean age was 68.2 years (range 45 to 90) for the laser group and 67.4 years (range 54 to 82) for the TURP group. The mean AUA symptom score was 22 for the laser group and 21 for the TURP group. The mean peak uroflow rate was 7.6 +/- 3.4 mL/s for the laser group and 6.5 +/- 4.0 mL/s for the TURP group. At 12 months of follow-up, the mean AUA symptom score had decreased to 7 (-69.5%) for the laser group and to 3 (-80.9%) for the TURP group. The mean peak uroflow rate increased to 15.4 mL/s (+ 107.8%) for the laser group and to 16.7 mL/s (+ 150.7%) for the TURP cohort. Seventy-five percent of the laser group had a 50% or greater decrease in their individual AUA symptom score compared with 93% of the TURP group. Sixty-five percent of the laser cohort had a 50% or greater increase in their peak uroflow rate compared with 75% of the TURP cohort. CONCLUSIONS: Laser prostatectomy produced improvements in the peak flow rate and symptom score similar to those produced by TURP. The patients who underwent laser treatment required a longer period to reach maximum improvement, which probably reflects the lack of tissue debulking at the time of surgery. Further improvement in laser technology will be required to produce more immediate results.

Aged↗
PubMed1999

Low-power v high-power KTP laser: improved method of laser ablation of prostate.

BACKGROUND AND OBJECTIVE: Current treatment technique for laser prostatectomy involve Nd:YAG wavelength at 60 to 80 W. Use of the KTP wavelength in addition to Nd:YAG allows for vaporization of more tissue, decreasing the amount undergoing coagulation necrosis. In this study, we compared 20 W and 40 W of KTP laser energy in conjunction with the Nd:YAG wavelength for the treatment of benign prostatic hyperplasia (BPH). PATIENTS AND MATERIALS: A total of 50 consecutive patients underwent laser ablation of the prostate, with 38 patients (Group I) receiving treatment with 20 W of the KTP and 60 W of the Nd:YAG wavelengths. The other 12 patients (Group II) underwent treatment with 40 W of KTP and 60 W of Nd:YAG laser energy. The patients had an initial evaluation consisting of American Urological Association (AUA) Symptom Score, uroflowmetry, transrectal ultrasonography for prostate volume measurement, and assay of prostate specific antigen (PSA) serum level. The patients were seen in follow-up at 1, 3, and 6 months. RESULTS: The mean symptom score decreased from 23.4 to 8.9 from Group I and from 18.2 to 3.5 for Group II at the 6-month follow-up. The mean peak urinary flow rate increased from 8.4 to 15.4 mL/sec Group I and from 8.3 to 16.5 mL/sec in Group II at the 6-month follow-up. CONCLUSIONS: The patients treated with the 40 W of KTP laser energy experienced a more rapid and sustained improvement in symptom score than those treated at 20 W. The improvement in peak urinary flow rate was approximately the same in the two groups.

Aged↗
PubMed1998

A randomized prospective study of transurethral electrovaporization vs laser ablation of the prostate in men with benign prostatic hypertrophy.

OBJECTIVE: A prospective randomized study comparing transurethral electrovaporization (TVP) vs laser ablation of the prostate was undertaken to compare the efficacy and safety of the procedures. METHODS: A total of 31 patients underwent treatment, with 20 patients receiving electrovaporization surgery and 11 patients undergoing laser treatment. Patients underwent initial evaluation consisting of an American Urological Association (AUA) symptom score, prostate specific antigen (PSA), uroflowometry, pressure flow, and transrectal ultrasound for prostate volume. Patients were seen in follow-up at 1, 3 and 6 months. RESULTS: A total of 31 patients with a 2:1 randomization of TVP to laser treatment were enrolled. The laser patients had a mean pre-operative AUA symptom score of 19.0 and scores of 9.0, 6.0 and 5.0 at 1-, 3- and 6-month follow-up. The TVP patients had a mean pre-operative symptom score of 22.0 and scores of 7.0, 8.0 and 5.0 at 1-, 3- and 6-month follow-up. Mean peak uroflow (PF) rate pre-operative was 10.7 for the laser group and 7.7 for the TVP group. At 1-, 3- and 6-month follow-up, mean PF rates of 13.3, 17.6 and 16.5 were present for the laser patients and 15.0, 17.5 and 14.2 for the TVP group. The differences were not statistically significant. There were 6 complications in the laser patients and 7 complications in the TVP group. Operative time was a mean of 27 min for the laser patients and 46 min for the TVP group, and the difference in operative time was statistically significant. CONCLUSION: At 6-month follow-up the improvement in symptoms score and peak flow rate are comparable in both treatment groups. The electrovaporization procedure required significantly longer to perform than the laser procedure. Long-term follow-up is required to see if these results remain sustainable for electrovaporization therapy.

Aged↗
PubMed1998

Electrovaporization of the prostate versus laser ablation of the prostate in men with benign prostatic hypertrophy: a pressure-flow analysis.

PURPOSE: To urodynamically assess the outcome results in a prospective cohort study of electrovaporization of the prostate (TVP) versus laser ablation of the prostate (LAP) in men with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: A randomized cohort of 10 men were enrolled to undergo a TVP procedure and a second cohort of 10 patients to undergo LAP. Preoperatively and at the 6-month follow-up all patients underwent a pressure-flow urodynamic study. Transrectal ultrasound for prostatic volume was performed at the time of enrollment and at the 6-month follow-up. RESULTS: Preoperatively, all patients except 1 were in the obstructed or equivocal range according to the Abrams-Griffin nomogram. At the 6-month follow-up the mean maximum detrusor pressure (Pdet) maximum flow rate (Qmax) for both groups of patients moved into the equivocal range. The mean prostatic volume for the TVP patients decreased 20% in comparison to a 2% decrease in prostatic volume for LAP patients. Both groups experienced similar decreases in the American Urological Association (AUA) symptom scores and increases in peak flow rates at the 6-month follow-up. CONCLUSION: Both treatment groups demonstrated a relief in symptoms by urodynamic assessment and AUA symptom score. This was present even though both groups had only a minimal decrease in prostatic volume. A reduction in prostate volume does not appear to be a prerequisite for improvement of symptoms from BPH.

Aged↗
PubMed1998

Renal cell carcinoma in native kidneys of patients with end stage renal disease.

OBJECTIVE: To determine prevalence of renal cell carcinoma in a cohort of patients with end stage renal disease who underwent nephrectomies for suspicious cysts or masses. METHODS: A retrospective review of patients with end stage renal disease who were receiving hemodialysis and underwent nephrectomies were identified and those charts were reviewed. RESULTS: Twenty patients, from a total of 400 patients with end stage renal disease, had nephrectómies preformed for various reasons. Of these twenty patients, four were found to have renal cell carcinoma with an occurrence rate of 5% in these patients. At followup from 1-9 years, all patients are alive without evidence of disease. CONCLUSIONS: Patients with end stage renal disease have an increased prevalence of renal cell carcinoma. While the patients in this series have a 100% survival at 1-9 year follow-up, the overall survival rate in published reports is 35%. The need is to identify patients at high risk for the development of this disease and perform annual screening.

Adult↗
PubMed1996

Laparoscopic pelvic lymphadenectomy.

The most common laparoscopic procedure performed in urologic surgery today is the pelvic lymphadenectomy. A good understanding of basic laparoscopic technique and the anatomy of the pelvis will allow the surgeon to avoid pitfalls and lead to a successful operation.

Humans↗
PubMed1996

Neointimized Gore-Tex graft for ureteral prosthesis in the dog.

OBJECTIVES: To determine the feasibility of replacing a ureteral segment with a neointimized Gore-Tex graft. METHODS: Seven adult mongrel dogs underwent a two-stage operative procedure. The first procedure involved arterializing the graft to stimulate spread of a luminal neoendothelium by transmural capillary growth. Eight weeks after the initial procedure, a segment of the ipsilateral ureter was replaced with a segment of the neointimized graft. RESULTS: Histologic evaluation of a portion of the graft removed during the second procedure demonstrated transmural neocapillary ingrowth in all grafts; however, there was no neoendothelial growth on the luminal surface. In 5 dogs the graft was occluded with blood clot and was not suitable for a ureteral prosthesis. In 2 dogs the graft was patent and was successfully incorporated into the urinary system. After 1 year of observation, both of these dogs maintained a patent ureter and had no evidence of hydronephrosis on intravenous urogram. CONCLUSIONS: These data demonstrate that a Gore-Tex graft can be used as a ureteral prosthesis in the dog. The importance of preliminary arterialization, however, remains to be determined.

Animals↗
PubMed1995

Squamous cell carcinoma of the lung with metastasis to the penis.

Neoplasms metastatic to the penis are uncommon. Metastatic lesions from the lung to the penis are rare, with only eight case reports in the world literature. In this report we describe a patient with a single metastatic lesion to the penis and bilateral adrenal metastases from recurrent squamous cell carcinoma of the lung.

Adrenal Gland Neoplasms↗
PubMed1995

Seminal vesicle abscess: a case report and review of literature.

Seminal vesicle abscess, a rare urologic entity, is usually diagnosed with computerized tomography (CT) scan. We report a case of seminal vesicle abscess that required a transrectal ultrasonography to confirm the diagnosis. An analysis of 20 cases of seminal vesicle abscess reported in the literature is also reviewed.

AIDS-Related Opportunistic Infections↗
PubMed1994

Duplication of inferior vena cava: its importance in retroperitoneal surgery.

Anomalies of the inferior vena cava arise infrequently. Knowledge of their presence can be established preoperatively with a variety of radiologic studies. This knowledge can prevent hemorrhagic complications from occurring during surgery. We present a case report of a patient with renal cell carcinoma and duplication of the inferior vena cava.

Carcinoma, Renal Cell↗
PubMed1993

The development of urologic complications in relationship to bladder pressure in spinal cord injured patients.

The medical records of 88 patients followed through our spinal cord injury clinic were reviewed to determine if elevated intravesical pressures result in more urologic complications than are seen with low pressure bladders. Fifty-two of the patients were noted to have a high bladder pressure (sustained detrusor pressure greater than 40 cm water) on cystogram while 36 had low pressures. All patients had routine urine cultures, urodynamics, ultrasonography, radioisotope renal scans, and excretory urograms. Bladder management was directed at maintaining a low bladder pressure and included one or more of the following: intermittent catheterization, anticholinergics, alpha blockers, transurethral sphincterotomy, or indwelling catheters. Average follow-up was 6 years. Mild degrees of hydronephrosis were noted in seven (14 percent) of the patients with a high pressure bladder and in one (3 percent) with a low pressure bladder. Pyelonephritis was noted in two (4 percent) with high bladder pressure and two (5 percent) with low bladder pressure. Preservation of renal function occurred as the result of patient compliance with bladder management and bladder pressure. Sustained high detrusor pressure, when not corrected, leads to upper tract deterioration which was reversed by aggressive lower tract management.

Humans↗
PubMed1991

Clinical and immunological response to nifedipine for the treatment of interstitial cystitis.

Nifedipine is a calcium channel antagonist known to inhibit smooth muscle contraction and cell-mediated immunity. The clinical and local immune response to nifedipine was investigated in an open trial with 10 female interstitial cystitis patients, whose disease was diagnosed according to the consensus criteria developed in 1987 at a National Institutes of Health workshop. To evaluate the symptoms and clinical response of the patients objectively we scored the symptoms of frequency, urgency, nocturia, dysuria and suprapubic pain on a scale of 0 to 2. Nifedipine was administered as a single daily dose determined by a dose-titration test. Urinary interleukin-2 inhibitor activity, a marker of cell-mediated inflammation, was measured using a murine interleukin-2 dependent cell line. Before nifedipine therapy the symptom scores (total of the 5 symptoms) ranged between 5 and 9, and after 2 months they ranged between 0 and 6. Of the 9 patients followed for at least 4 months only 1 failed to have a significant clinical improvement, 5 showed at least a 50% decrease in symptom scores and 3 were asymptomatic. Drug side effects were minimal. Urinary interleukin-2 inhibitor activity before nifedipine therapy confirmed the presence of cell-mediated inflammation. After 4 months of therapy interleukin-2 inhibitor activity was normal in 7 of 9 patients regardless of the severity of symptoms, which indicated that nifedipine exerted an immunosuppressive effect. Although our data suggest that nifedipine is an efficacious, well tolerated, convenient oral medication for the treatment of interstitial cystitis, the true value of nifedipine for patients with this disease must be determined by a prospective, randomized trial of nifedipine versus placebo.

Adult↗
PubMed1991

Fibrinolysis, thrombocytopenia, and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy.

High-dose interleukin-2 (IL-2) immunotherapy can cause hypotension, respiratory distress, interstitial edema, and thrombocytopenia, similar to endotoxic shock. We have observed that IL-2 has no direct effect on coagulation factors in vitro, but it has been observed to alter the coagulant properties of vascular endothelium. Accordingly, we investigated the possibility that IL-2 infusions initiate plasma fibrinolysis and disseminated intravascular coagulation (DIC). We studied the clinical course, platelet count, and coagulation profile in response to IL-2 infusion in seven patients, two with metastatic melanoma and five with metastatic renal cell carcinoma. Every patient experienced hemodynamic instability and thrombocytopenia, and one patient suffered an unusual complication, mesenteric thrombosis. No patient had appreciable changes in the prothrombin time or the partial thromboplastin time, nor did factors V or VIII decline in the two patients observed. In four patients examined, we found decreased titers of Hageman factor (factor XII), high molecular weight kininogen, prekallikrein, and plasma thromboplastin antecedent, as if these had been consumed by reactions of the intrinsic pathway of thrombin formation. Circulating D-dimer fragments were found in the plasma of every patient at some point during each infusion cycle, and we observed decreased titers of plasminogen in the four patients just mentioned, suggesting that IL-2 infusions initiated fibrinolysis. Taken together, the clotting factor derangements and related toxicity phenomena cannot be ascribed firmly to DIC. Activation of the intrinsic (contact) system of coagulation, however, may provide one link between the vascular endothelial surface alterations caused by IL-2 infusions and the development of the systemic toxicity that resembles septic shock.

Adult↗